




	EC50
anti-Trop-2-Compound **1**	46.66
anti-Trop-2-Compound **2**	173.8

Fig. 1A




	EC50
anti-Trop-2-Compound **1**	337.0
anti-Trop-2-Compound **2**	302.9

Fig. 1B




	EC50
anti-Trop-2-Compound **1**	91.20
anti-Trop-2-Compound **2**	203.5

Fig. 1C




	EC50
anti-Trop-2-Compound **1**	46.66
anti-Trop-2-Compound **3**	8.025

Fig. 2A




	EC50
anti-Trop-2-Compound **1**	337.0
anti-Trop-2-Compound **3**	32.47

Fig. 2B




	EC50
anti-Trop-2-Compound **1**	91.20
anti-Trop-2-Compound **3**	17.46

Fig. 2C




	EC50
anti-Trop-2-Compound **1**	46.66
anti-Trop-2-Compound **4**	140.5

Fig. 3A




	EC50
anti-Trop-2-Compound **1**	337.0
anti-Trop-2-Compound **4**	177.3

Fig. 3B




	EC50
anti-Trop-2-Compound **1**	91.20
anti-Trop-2-Compound **4**	~ 7.817e-048

Fig. 3C




	EC50
anti-Trop-2-Compound **1**	46.66
anti-Trop-2-Compound **5**	40.45

Fig. 4A




	EC50
anti-Trop-2-Compound **1**	337.0
anti-Trop-2-Compound **5**	258.0

Fig. 4B




	EC50
anti-Trop-2-Compound **1**	91.20
anti-Trop-2-Compound **5**	117.5

Fig. 4C




	EC50
anti-Trop-2-Compound **1**	46.66
anti-Trop-2-Compound **6**	60.30

Fig. 5A



	EC50
anti-Trop-2-Compound **1**	337.0
anti-Trop-2-Compound **6**	104.6

Fig. 5B



	EC50
anti-Trop-2-Compound **1**	91.20
anti-Trop-2-Compound **6**	44.75

Fig. 5C



PBS/Vehicle
anti-Trop-2 antibody, 5 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 5 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 2 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 5 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 2 mg/kg, i.v biw x 4
*** P < 0.001, Two Way Anova with
Dunnett's Multiple Comparison Test
to PBS/Vehicle.
Data=Mean + SEM, N=6
Tumor volume
change %
400
300
200
100
0
-100
Dosing
0
7
14
21
28
35
42
Day after initial treatment
***
***
***
***

Fig. 6A



PBS/Vehicle
anti-Trop-2 antibody, 10 mg/kg, i.v biw x 4
anti-Trop-2 antibody, 3 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 10 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 3 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 10 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 3 mg/kg, i.v biw x 4
*** P < 0.001, Two Way Anova with Dunnett's Multiple Comparison Test To Ab control.
Data=Mean + SEM, N=6-8
Tumor volume change (%)
1000
800
600
400
200
0
-200
0 10 20 30 40 50 60 70 80 90 100
Days after initial treatment
Dosing
***
***

Fig. 6B



NCI-N87
Tumor Volumn (mm³)
1600
1400
1200
1000
800
600
400
200
0
Dosing
0
10
20
30
40
50
Days after initial treatment
*
***
TGI
at day 22
PBS/Vehicle
anti-Trop-2 antibody, 15 mg/kg, i.v biw x 4
anti-Trop-2 antibody, 5 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 15 mg/kg, i.v biw x 4 99.7%*
ADC-CL2A-SN38, 5 mg/kg, i.v biw x 4 45.1%
anti-Trop-2-Compound 1, 15 mg/kg, i.v biw x 4 66.6%*
anti-Trop-2-Compound 1, 5 mg/kg, i.v biw x 4 42.5%
* P < 0.05, ***P < 0.001, Two Way
Anova with Dunnett's Multiple
Comparison Test to PBS/Vehicle.
Data=Mean + SEM, N=8

Fig. 7



BxPC3
Tumor volume change (%)
1400
1200
1000
800
600
400
200
0
-200
0 7 14 21 28 35 42 49
Days after initial treatment
Dosing
***
***
***
***
Vehicle /PBS
anti-Trop-2 antibody, 10 mg/kg, i.v biw x 4
ADC-CL2A-SN38, 10 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 25 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 10 mg/kg, i.v biw x 4
anti-Trop-2-Compound 1, 3 mg/kg, i.v biw x 4
***P < 0.001, **P < 0.01 Two Way Anova with Dunnett's Multiple Comparison Test to Vehicle/PBS. Data=Mean + SEM, N=6
TGI % at day 21
TGI % at day 41
TGI % at day 48
97.9% 79.7% 76.1%
100.0% 66.3% 53.9%
85.3% 67.9% 61.5%
99.0% 86.3% 79.8%

Fig. 8



%Free Drug Release from ADC (A370 peak area)
%Free Drug Release (A370)
0
5
10
15
20
25
30
35
40
0
50
100
150
Incubation time (h)
ADC-CL2A-SN38
anti-Trop-2-Compound 1
Buffer

Fig. 9



Anti-Trop-2 antibody & ADC PK in Swiss Webster Mouse,
10 mg/ml IV, n=3
anti-Trop-2 antibody
anti-Trop-2-Compound 1_Total Ab
anti-Trop-2-Compound 1_ADC
Concentration (µg / mL)
1000
100
10
1
0.1
0.01
0
100
200
300
400
500
600
Time Point (hr)

Fig. 10